Actually your question is valid and this is likely to happen. However I personally not looking at approval itself as it is far off. I am looking at the jump due to publicity and realization that CYDY has an effective drug.
The other thing which I have stated before is - there are 3 categories under which the competition is happening
1. Treating effectively the moderate to severe hospitalized patients - LERO, Malaria drug and GILD drug are leaders. There are few others IL6 and Cytokine storm treaters are followers.
These may show quick results
2. The antiviral drugs - to treat patients that are not infected but not severely sick - treat them so they do not spread it further
Medium term - many approved or not approved antiviral drugs are under
3. The vaccine group - this is long term and many large and small pharma are trying this - this is crowded market and we will see 2/3 companies will emerge as winners and others will stop the efforts.
Moderna is clear leader NVAX,AKER and about to start the trials - PFE, JnJ etc are still in preclinical phase and will start the trials in near future. All are starting with healthy individuals so the real efficacy of vaccine is away.
4. The antibody group - the Israeli co and universities - they also have long path ahead
News 
Market Data 
Discover 
